TME Pharma announces strategic plan to externalize and monetize second clinical stage asset NOX-E36
. NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies…
. NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies…
Meilensteine in Herz-Kreislauf-, Nieren- und Stoffwechselgesundheit (CRM) sowie Onkologie erreicht Weitere Daten werden…
KYAN Technologies, a vanguard combinatory drug development solutions provider, is thrilled to announce a strategic partn…
Attgeno AB today announces a research collaboration targeting to explore Supernitro (PDNO) as a new potential treatment…
Laut einer Analyse von Market Research.biz ist laut einer neuen Studie zum Behandlung der Nierenfibrose Market ein detai…
On September 14, the winners of the "Most Innovative Product" award in the category of leap innovations were announced a…
PRS-220, an oral inhaled Anticalin protein targeting CTGF, a fully proprietary drug candidate for respiratory disease, i…
PRS-220 ist ein oral-verabreichtes, inhalatives Anticalin®-Protein, das gegen CTGF gerichtet ist; der vollständig firmen…
First-ever data on therapeutic miR-132 inhibition in a large animal model of nonischemic heart failure with cardiac hype…
Respiratory Care Devices Market - Key Players Some of the key players in the global respiratory care devices market ar…